AstraZeneca’s Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.
AstraZeneca’s Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
Where Today's News Shapes Tomorrow
